Andor Technology plc, a world leader in scientific imaging and modular spectroscopy solutions, announces the launch of its multi-wavelength imaging portfolio. The portfolio comprises of the TuCam, a state-of-the-art two camera adapter for simultaneous imaging with maximized field of view, as well as the Optosplit II, a cost-effective dual emission splitter that divides an image into two separate spatially equivalent components that can be displayed side by side on a single camera sensor.
Well suited to fast, concurrent detection of two different fluorophores in experiments such as co-localization FRET or ratiometric ion signalling, TuCam and Optosplit II are compatible with Andor’s complete range of market leading low light imaging cameras, including iXon and Luca EMCCDs, Clara interline CCD and the Neo and Zyla sCMOS. A range of simultaneous multi-channel acquisition and complementary analysis software options are also available. Further flexibility can be accessed by converted TuCam into a high performance camera switching device, facilitating fast switching between two different acquisition technologies for example.
The robust design of TuCam ensures superior optical and mechanical stability and ease of alignment. Available as C- or CSUX-mount versions and availing of a wide range of high quality wavelength or polarization filter sets, TuCam also features high quality achromatic lenses, industry-leading transmission, very low distortion and excellent registration between camera channels. A unique 22mm aperture certifies compatibility with large format sensors for wide field of view imaging, as offered by the Neo and Zyla sCMOS cameras.
TuCam can be used with two identical cameras to achieve simultaneous and synchronous fast imaging or it can act as a switch between two different detectors, thus ensuring ease of use for any application. If two cameras are not available and dual wavelength imaging is required Andor offer the Optosplit II, thereby tailoring the needs of any laboratory or imaging facility.
Filed Under: Drug Discovery
